Bio-Replicon is an early-stage biotechnology company founded by graduates of the MSTC (Master of Science in Technology Commercialization) program at McCombs School of Business of the University of Texas at Austin.
We are a startup company aimed at commercializing a new generation of medical diagnostics to help doctors make better clinical decisions.
Our first product, SeptiCatch, is aimed at early detection of sepsis. We plan to develop a commercial version of Sepsis diagnostic test based on its proprietary universal bacteria MDx test technology and license the IP to key current players in the IVD industry. Bio-Replicon holds exclusive rights to a patent pending MDx technology capable of detecting a full range of pathogen bacteria and identifying their specific types within four hours. We are currently in the prelaunch stage of development.
2012 – Bio-Replicon is formed.
2012 – Bio-Replicon participated in Venture Labs Investment Competitions
2012 – Bio-Replicon won 3rd place at “Idea to Product Competition” held at the University of Texas at Austin
2013 – Bio-Replicon was a finalist of business plan competition of AUTM (Association of University Technology Managers) Venture Forum